Adult/Influenza
Update of ACIP [June 22-23, 2022]

Andrew Kroger M.D., M.P.H.
Medical Officer
Immunization Services Division

National Adult Immunization and Influenza Summit
June 30, 2022
Andrew Kroger is a federal government employee with no financial interest or conflict with the manufacturer of any product named in this presentation.

I will discuss off-label uses for MMRII and Priorix.

The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.
Overview

- Influenza
- Priorix (new MMR vaccine)
Influenza
65 Years Old and Older: Higher Dose and Adjuvanted Vaccines

- ACIP voted for preferential use of higher dose or adjuvanted influenza vaccines for persons 65 years old or older
- Includes these vaccines:
  - Higher Dose: high-dose influenza vaccine (Fluzone High-Dose), Recombinant Influenza Vaccine (Flublok)
  - Adjuvanted: ajuvanted influenza vaccine (Fluad)
- Based on Evidence to Recommendations Process
- No preference between these three
- If none of the three are available, vaccinate with another age-appropriate influenza vaccine
Influenza Vaccine Strains: Egg-Based

- A/Darwin/9/2021 (H3N2)-like - New
- A/Victoria/2570/2019 (H1N1)pdm09like virus - Same
- B/Phuket/3073/2013 (Yamagata lineage)-like - Same
- B/Austria/1359417/2021 (Victoria lineage)-like - New
Influenza Vaccine Strains: Cell-Culture and Recombinant

- A/Darwin/6/2021 (H3N2)-like – New
- A/Wisconsin/588/2019 (H1N1)pdm09-like – Same
- B/Phuket/3073/2013 (Yamagata lineage)-like – Same
- B/Austria/1359417/2021 (Victoria lineage)-like – New
Influenza Vaccine Strains: Cell-Culture and Recombinant

- A/Darwin/6/2021 (H3N2)-like – New – Different from Egg
- A/Wisconsin/588/2019 (H1N1)pdm09-like – Same – Different from Egg
- B/Phuket/3073/2013 (Yamagata lineage)-like – Same – Same as Egg
- B/Austria/1359417/2021 (Victoria lineage)-like – New – Same as Egg
New Formulation

- ccIIIV (Flucelvax) now approved for 6 months of age and older
Measles-Mumps-Rubella Vaccine (Priorix)
Priorix

- ACIP voted to recommend GlaxoSmithKline’s Priorix according to currently recommended schedules and off-label uses as an option to prevent measles, mumps, and rubella
- Based on Evidence to Recommendations Process
- An alternative to MMRII (Merck)
Adult MMR Recommendations

- MMR vaccine is recommended for adults who lack evidence of immunity to any one of these microbes: measles, mumps, or rubella
  - evidence of Immunity
    - born before 1957 (HCP excluded)
    - documented laboratory evidence
    - age-appropriate evidence of vaccination (varies by age and microbe)
Adult MMR Recommendations: Number of Doses

- **Two doses:**
  - health care providers (even born before 1957)
  - post-secondary school students
  - international travelers

  - *Exceptions (need one dose)*
    - positive serology to measles AND mumps (or other single-component immunity evidence for BOTH), but negative for rubella (susceptible to rubella)
    - completing a two-dose series with one dose administered previously (vaccination prior to one year of age does NOT count toward two dose recommendation)

- **One dose:**
  - Most other adults
Some Off-label Uses: Adults

- Vaccination at 6 months to 12 months of age
- Three doses in a mumps outbreak
- Avoid conception one month after administration of MMRII or Priorix